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Abstract: The tumor suppressor p53 is inactivated by mutation in approximately 50% of human
cancers. Small molecules that bind and stabilize those mutants may represent effective anticancer
drugs. Herein, we report the tumor cell growth inhibitory activity of carbazole alkaloids and amino
derivatives, as well as their potential activation of p53. Twelve aminocarbazole alkaloids were
semi-synthesized from heptaphylline (1), 7-methoxy heptaphylline (2), and 7-methoxymukonal
(3), isolated from Clausena harmandiana, using a reductive amination protocol. Naturally-occurring
carbazoles 1–3 and their amino derivatives were evaluated for their potential effect on wild-type and
mutant p53 activity using a yeast screening assay and on human tumor cell lines. Naturally-occurring
carbazoles 1–3 showed the most potent growth inhibitory effects on wild-type p53-expressing cells,
being heptaphylline (1) the most promising in all the investigated cell lines. However, compound 1
also showed growth inhibition against non-tumor cells. Conversely, semi-synthetic aminocarbazole
1d showed an interesting growth inhibitory activity in tumor cells expressing both wild-type and
mutant p53, exhibiting low growth inhibition on non-tumor cells. The yeast assay showed a potential
reactivation of mutant p53 by heptaphylline derivatives, including compound 1d. The results
obtained indicate that carbazole alkaloids may represent a promising starting point to search for new
mutp53-reactivating agents with promising applications in cancer therapy.
Keywords: aminocarbazoles; heptaphylline; alkaloids; tumor; p53; mutant
1. Introduction
Carbazole alkaloids natural products are mostly isolated from higher plants of Ru-
taceae family and major components of the Clausena genus [1,2]. With the isolation of
carbazole core from coal tar in 1872 [3] and the description of the antimicrobial murrayanine
in 1965 [4], the interest on these alkaloids began. Since then, natural-occurring carbazole
alkaloids have been reported to exhibit a broad pharmacological profile, including ac-
tivities such as antitumor (i.e., heptaphylline 1, Figure 1) [5], 7-methoxy-heptaphylline
(2) [6], 2-hydroxy-7-methoxy-9H-carbazole-3-carbaldehyde or 7-methoxy-mukonal (3) [7]),
antiplasmodial (i.e., compounds 1 [8] and 3 [7]), antiplatelet aggregation, and vasorelax-
ing (i.e., clausine E (4) [9]), antibacterial (i.e., clausamine B (5), clausine F (6) [10], and
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clausenal (7) [11]), antifungal (i.e., compound 7 [11]), and antidiabetic (i.e., koenidine
(8) [12]). Recently, heptaphylline (1) was reported to induce apoptosis in a human colon
adenocarcinoma cell line [13] and was considered a promising model for new anticancer
drugs. In addition, the carbazole nucleus can be easily functionalized mainly at positions 3,
6, and 9 to obtain bioactive derivatives [2,6]. For instance, analogue 9 was reported with
anti-Alzheimer properties [14], and compound 10 with activity against human immunod-
eficiency virus, type-1 (HIV-1) [15]. Derivatives 11 and 12 of carbazole 1 were found to
exhibit strong cytotoxicity against NCl-H187 and KB cells, 138 fold stronger than ellipticine
standard [6,16–19] while N-substituted derivatives, such as compounds 13 and 14, were
reported as tumor growth inhibitors against leukemia cells ECM, Jurkat, and Raji with
concentration that induces 50% of growth inhibition (IC50) values around 12 µM [17].
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Inhibitors of tumor cell lines have been associated to several mechanisms, one of which
being through the p53 pathway. The tumor suppressor protein p53 is a transcription factor
that plays a key role in the prevention of cancer development, mainly due to its major
role in cellular events such as apoptosis, cell cycle progression, and DNA repair [20,21].
However, over 50% of p53 proteins present missense mutations, generating a defective
protein in high levels in cells due to the impairment of MDM2 (murine doble minute 2)
mediated negative feedback, which is responsible for p53 degradation. p53 Protein is known
as the guardian of the genome because one of the most important p53 functions is the
ability to activate apoptosis and the disruption of this process can be correlated with tumor
progression and chemoresistance [22]. In tumor cells, the restoration of p53 function has
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shown to be highly effective against tumor cells, thus reactivating mutant p53 has been a
goal in anticancer drug development [23]. Some small molecules in the group of carbazole
alkaloids have been reported to reactivate mutant p53 by restoration the wild-type (wt)
structure/function [24,25]. For example, PhiKan083 (15), an amino derivative of the carbazole,
emerged from an in silico screening [26] and was reported as a small molecule for restoration
of wild-type like p53 conformation by targeting Y220 mutation [26,27]. This derivative 15
established electrostatic and hydrogen bonding interactions with residues of Y220 which gave
additional stability to Y220 mutant p53. This particular mutation creates a druggable surface
crevice and PhiKan083 (15) binds to this crevice and stabilizes the structure of this mutant
p53 [27,28]. Up to date, none of the natural isolated carbazole alkaloids or their chemical
modified ana was reported to have effect on p53 mutants. Herein, a series of semi-synthetic
aminocarbazoles was synthesized from naturally-occurring heptaphylline (1), and their tumor
cell growth inhibition and potential activity on p53 were studied.
2. Results and Discussion
2.1. Semi-Synthesis of Aminocarbazole Alkaloids by Direct Reductive Amination
The reaction of carbonyl groups, aldehydes, or ketones with amines in the present of
reducing agents to give corresponding amines, known as reductive amination (of carbonyl
compounds) or reductive alkylation (of amine compounds) is one of the most useful
and important methods in the synthesis of different kind of amines as well as a powerful
reaction to obtain drug candidates [29]. The choice and understanding of the reducing agent
are essential for the selection of the reaction conditions. Sodium triacetoxyborohydride
[NaBH(OAc)3, STAB] was reported as the most powerful reducing agent in direct reductive
amination due to its stability and safety.
Reductive aminations of 1, 2, and 3 were performed in an one-pot conversion of their
carbonyl group in the present of STAB with two different solvents—dried tetrahydrofu-
ran (THF) or dried 1,2-dichloroethane (DCE) with selected amines precursors present in
inhibitors of p53:MDM2 interaction. The reaction mixtures were stirred under nitrogen
gas until no further developments to yield aminocarbazole alkaloids derivatives 1a–1e,
2a–2f, and 3a (Table 1). Products were treated with different work-up procedures before
purification, as described in the experimental section.
Generally, in the present of STAB, the reactions of 1, 2 and 3 with primary amines yield
secondary amines (entry 3–5 and 8–10), via imine intermediates, and the reaction with
secondary amines yield tertiary amines (entry 1–2, 6–7 and 11–12), via enamine intermedi-
ates. The final products were categorized into 3 groups, alkylated linear aminocarbazoles,
compounds 1a, 2a, and 3a, heterocyclic aminocarbazoles, compounds 1b, 2b, and 2f, and
halogenated aminocarbazoles, compounds 1c–1e and 2c–2e. The reactions mostly showed
no further development between 3–10 days. All the reactions required long reaction times
due to the steric hindered of the hydroxyl at position 2 and/or prenyl group at position 1.
Aminocarbazoles modified from 2, compounds 2a–2f, and from 3, compound 3a, required
longer reaction time than those derived from 1, compounds 1a–1e, in both solvent condi-
tions. These longer times should be related to the effect of the methoxy electron donating
group at position 7. The reductive amination with primary amines was faster than with
secondary amines (entry 4–6 and 8–10). Reactions performed in DCE required shorter
times and produced higher yields (3–5 days, 34–90%) compared to those performed in THF
(3–10 days, 13–51%), and these results are in agreement with previous reports [30]. All the
compounds were confirmed by one- and two-dimensional NMR and high-resolution mass
spectrometry. The chemical shift of protons and carbons of 1, 2, and 3 were accordance to
the literature [31,32]. The analysis of (+) HRMS-ESI, 1H, 13C NMR, HSQC, HMBC, and
X-ray crystallographic data (in case of compound 1b) revealed the success of the reductive
amination to produce amine derivatives. Compounds derived from 1 and 2, showed
the proton H-1′ signal as a doublet (d) with chemical shift δ values of c.a 3.50–3.68 ppm
while proton H-3′ signal appeared as a singlet with δ values c.a 3.74–3.83 ppm. The pro-
ton signal of one of the methyl groups of the prenyl substituent appeared as a singlet at
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c.a 1.90 ppm while another methyl signal was presented as a narrow doublet at c.a 1.76 ppm
due to the correlation to the H-1”. Aminocarbazoles derived from 1, compounds 1c, 1d, 1e,
and compounds derived from 2, compounds 2c, 2d, and 2e, presenting secondary amine
moieties showed the chemical shift of proton H-5′ with δ values c.a 4.14 and 4.05 ppm,
respectively appearing as singlets (see in experimental section). We also summary the key
protons of amine derivatives obtained from substrate 1 and 2 as shown in Figure 2. For
semi-synthetic derivatives from 1, the signals of protons H-5, appeared as doublets with δ
values c.a 7.89–7.90 ppm, H-6 as doublet-doublet-doublet with δ values c.a 7.15–7.16 ppm,
H-7 as doublet-doublet δ values c.a 7.28–7.31 ppm, and H-8 as doublet with δ values
c.a 7.36–7.38 ppm, respectively. For semi-synthetic derivatives of 2 and 3, having a methoxy
group at position 7, the proton signals of H-6 appeared as doublet-doublet with δ values
c.a 6.71–6.78 ppm, and H-8 as doublets with δ values c.a 6.82–6.88 ppm, respectively.
Table 1. Semi-synthesis of aminocarbazoles compounds 1a–1e, 2a–2f, and 3a from natural-
occurring carbazoles heptaphylline (1), 7-methoxy-heptaphylline (2), and 7-methoxy-mukonal (3).
Sub. = substrate.
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Figure 2. Key protons for compounds 1a–1f and 2a–2h.
Compound 1b was obtained as in a crystal form in the mixture of methanol and
ethyl acetate. The X-ray crystallographic representation of compounds 1b is presented in
Figure 3. The Ortep diagram confirmed the structure of 1b, and the analyses of HSQC and
HMBC provided the correlations of compound 1b depicted (Figure 3). The key proton H-4
showed correlations with C-3′, C-2, and C-9a while H-5 showed correlations with C-7 and
C-8a. The proton of the indole group H-9 showed correlations with C-8 and C-9a while
proton H-3′ showed correlations with C-4′, C-2, and C-4.




Figure 3. Ortep view of compound 1b and its key HMBC correlations. 
2.2. Aminocarbaozoles Exhibit Tumor Growth-Inhibitory Effect 
The tumor cell growth inhibitory potential of aminocarbazoles was ascertained in 
human colon adenocarcinoma HCT116 and melanoma A375 cell lines expressing wild-
type (wt) p53, in colorectal HT-29-R273H, HuH-7-Y220, SW837-R248W, MDA-MB-468-
R273H, SF-268-R273H, and LS1034-G245S cell lines expressing mutant p53. All naturally-
occurring carbazoles showed a strong inhibitory effect, while their aminocarbazoles 1a–
1e, 2b–2e, and 3a showed moderate inhibitory effects (IC50 range between 4.5 to > 50 µM) 
in all tested cell lines (Table 2) in which heptaphylline (1) demonstrated marked antipro-
liferative activity. A promising activity could be observed with compound 1d, which dis-
played and evident growth inhibitory activity in cell lines expressing mutant p53, partic-
ularly in HT-29, MDA-MB-468, and LS-1034, and a significantly lower activity in non-
tumorigenic cells (Figure 4). 
Table 2. Growth inhibition (GI50) concentration of 1, 2, 3, and amino carbazoles 1a–1e and 2a–2e on human tumor cell 
lines. 











1 4.4 ± 1.1 14.0 ± 0.1 6.1 ± 0.3 7.2 ± 0.4 <3.13 - - - 
2 15.0 ± 1.0 23.0 ± 6.0 21.5 ± 0.5 30.5 ± 2.5 - 5.0 ± 0.3 - - 
3 4.7 ± 0.5 9.4 ± 0.7 6.3± 2.2 6.1 ± 1.2 - - - - 
1a > 50 >50 - - >50 - - - 
1b 18.1 ± 0.9 18.0 ± 1.9 > 50 23.0 ± 3.0 16.0 ± 2.0 - - - 
1c 22.6 ± 4.5 - 30.5 ± 0.5 29.0 ± 2.0 - - - - 
1d 15.5 ± 1.5 8.3 ± 1.0 28.5 ± 0.5 26.0 ± 2.0 18.0 ± 3.0 24.5 ± 1.5 20.0 ± 4.0 5.8 ± 0.8 
1e 30.6 ± 2.8 - >50 23.0 ± 1.0 - 38.2 ± 1.9 - - 
1f - - - - - - - - 
2a 22.3 ± 1.0 - 15.5 ± 3.5 18.0 ± 0.0 - 29.7 ± 1.8 - - 
2b 24.0 ± 4.0 28.5 ± 1.5 >50 >50 - >50 - - 
2c 25.0 ± 1.8 - 45.0 ± 3.0 >50 - 30.7 ± 3.7 - - 
2d 16.1 ± 3.5 - 23.0 ± 3.0 10.8 ± 1.3 - 27.8 ± 3.0 - - 
2e 27.0 ± 4.4 - 33.5 ± 5.5 37.5 ± 0.5 - 38.3 ± 3.2 - - 
2f - - - - - - - - 
2g - - - - - - - - 
2h - - - - - - - - 
3a 22.2± 0.9 - 15.5 ± 3.5 18.0 ± 0.0 - 29.7 ± 1.8 - - 
Etoposide 0.54 ± 0.1 1.52 ± 0.3 3.66 ± 0.7 0.9 ± 0.07 2.07 ± 0.15 0.85 ± 0.09 - - 
Concentration that induces 50% of growth inhibition (IC50) was determined by the sulforhodamine B (SRB) assay after 48 
h treatment. Data are mean ± standard error of the mean (SEM) of 3–4 independent experiments. Dash means not detected. 
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2.2. Aminocarbaozoles Exhibit Tumor Growth-Inhibitory Effect
The tumor cell growth inhibitory potential of aminocarbazoles was ascertained in
human colon adenocarcinoma HCT116 and melanoma A375 cell lines expressing wild-type
(wt) p53, in colorectal HT-29-R273H, HuH-7-Y220, SW837-R248W, MDA-MB-468-R273H,
SF-268-R273H, and LS1034-G245S cell lines expressing mutant p53. All naturally-occurring
carbazoles showed a strong inhibitory effect, while their aminocarbazoles 1a–1e, 2b–2e,
and 3a showed moderate inhibitory effects (IC50 range between 4.5 to > 50 µM) in all
tested cell lines (Table 2) in which heptaphylline (1) demonstrated marked antiproliferative
activity. A promising activity could be observed with compound 1d, which displayed
and evident growth inhibitory activity in cell lines expressing mutant p53, particularly in
HT-29, MDA-MB-468, and LS-1034, and a significantly lower activity in non-tumorigenic
cells (Figure 4).
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Figure 4. IC50 values of compound 1d in tumor cells expressing mutant p53 and in non-tumor-
igenic cells (HFF). The concentration that induces 50% of growth inhibition (IC50) was determined 
by SRB assay after 48 h treatment. Data are mean ± SEM of 3–4 independent experiments. 
2.3. Evaluation of Aminocarbazoles Potential Activation of p53 Using a Yeast-Based 
Screening Assay 
Compounds containing a carbazole scaffold have been identified and tested against 
a certain mutation of p53 and showed to stabilize the mutant in which the carbazole ring 
system is sandwiched in hydrophobic side chains [26]. In this work, to identify small mol-
ecules of aminocarbazoles that could restore p53 pathway signalling, three aminocaba-
zoles derived from heptaphylline (1b–d) and the natural compound 1 were tested for their 
ability to activate wt or mutant p53, using a previously developed yeast-based screening 
assay [33]. Among the tested compounds in cells lines, four were selected due to their 
highest growth inhibitory activity in tumor cells. In the yeast assay, yeast cells expressing 
wt p53 present a marked growth inhibition, which is reduced or abolished in case of mu-
tant p53. Compounds able to activate wt p53 or to restore the wild-type-like activity to 
mutant p53 will increase the growth inhibition induced by expression of the human pro-
tein in yeast [33]. Yeast cells expressing mutant or wt p53, and control yeast (transformed 
with the empty vector) were treated with 10 µM of each compound and its impact on 
yeast growth inhibition was evaluated. All the compounds tested were able to reactivate 
at least two of the mutant p53 forms studied, increasing their yeast growth inhibitory ef-
fect (Table 3). Among the compounds tested, only compound 1b was able to also activate 
wt p53 in yeast. It is of note that compounds 2 and 3 were cytotoxic in control yeast, and 
therefore these natural products were excluded from the assay. 
Table 3. Effect of heptaphylline and amine derivatives 1b–1d on the growth of yeast cells express-
ing wild-type (wt) or mutant p53. 
Mutant p53 1 1b 1c 1d 
R280K - - - - 
Y220C 71.17 ± 11.53 - - 47.83 ± 5.80 
G245D - 57.06 ± 13.03 34.73 ± 12.50 63.43 ± 11.50 
R273H - - - - 
R175H - - 41.50 ± 16.40 - 
R248W - - - 34.30 ± 2.97 
R248Q - - 52.90 ± 9.13 46.20 ± 5.27 
R273C - 47.30 ± 6.07 - - 
R282W - 42.33 ± 1.63 83.63 ± 7.16 - 
G245S 68.40 ± 12.20 47.87 ± 8.83 52.20 ± 6.90 55.33 ± 4.53 
wt p53 - 61.70 ± 11.1 - - 
Figure 4. IC50 values of compound 1d in tumor cells expressing mutant p53 and in non-tumorigenic
cells (HFF). The concentration that induces 50% of growth inhibition (IC50) was determined by SRB
assay after 48 h treatment. Data are mean ± SEM of 3–4 independent experiments.
2.3. Evaluation of A inocarbazoles Potential Activation of p53 Using a Yeast-Based
Screening Assay
Compounds containing a carbazole scaffold have been identified and tested against
a certain mutation of p53 and showed to stabilize the mutant in which the carbazole
ring system is sandwiched in hydrophobic side chains [26]. In this work, to identify
small molecules of aminocarbazoles that could restore p53 pathway signalling, three
aminocabazoles derived from heptaphylline (1b–d) and the natural compound 1 were
tested for their ability to activate wt or mutant p53, using a previously developed yeast-
based screening assay [33]. Among the tested compounds in cells lines, four were selected
due to their highest growth inhibitory activity in tumor cells. In the yeast assay, yeast cells
expressing wt p53 present a marked growth inhibition, which is reduced or abolished in
case of mutant p53. Compounds able to activate wt p53 or to restore the wild-type-like
activity to mutant p53 will increase the growth inhibition induced by expression of the
human protein in yeast [33]. Yeast cells expressing mutant or wt p53, and control yeast
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(transformed with the empty vector) were treated with 10 µM of each compound and its
impact on yeast growth inhibition was evaluated. All the compounds tested were able
to reactivate at least two of the mutant p53 forms studied, increasing their yeast growth
inhibitory effect (Table 3). Among the compounds tested, only compound 1b was able to
also activate wt p53 in yeast. It is of note that compounds 2 and 3 were cytotoxic in control
yeast, and therefore these natural products were excluded from the assay.
Table 3. Effect of heptaphylline and amine derivatives 1b–1d on the growth of yeast cells expressing
wild-type (wt) or mutant p53.
Mutant p53 1 1b 1c 1d
R280K - - - -
Y220C 71.17 ± 11.53 - - 47.83 ± 5.80
G245D - 57.06 ± 13.03 34.73 ± 12.50 63.43 ± 11.50
R273H - - - -
R175H - - 41.50 ± 16.40 -
R248W - - - 34.30 ± 2.97
R248Q - - 52.90 ± 9.13 46.20 ± 5.27
R273C - 47.30 ± 6.07 - -
R282W - 42.33 ± 1.63 83.63 ± 7.16 -
G245S 68.40 ± 12.20 47.87 ± 8.83 52.20 ± 6.90 55.33 ± 4.53
wt p53 - 61.70 ± 11.1 - -
Percentage of p53 reactivation induced by heptaphylline derivatives. Data were nor-
malized to the percentage of wtp53 growth inhibitory effect in yeast cells. Yeast expressing
human mutant p53 or wt p53 were treated for 42 h with the indicated compound. Re-
sults correspond to the percentage of wt p53-induced growth inhibition re-established by
compounds in yeast expressing mutant p53. Data are mean ± SEM of 3–6 independent
experiments. Dashes represent a reactivation effect lower than 30%.
Interestingly, in the yeast-screening assay, compound 1d demonstrated the most
promising activity in mutations involving codon 245 of p53, namely G245D and G245S. In
fact, through the antiproliferation assay, compound 1d displayed its greatest antiprolifera-
tive activity in LS-1034 expressing mutant p53 G245S.
3. Materials and Methods
3.1. Isolation
The root bark of Clausena harmandiana (Pierre) Guillaumin (Rutaceae) was collected in
Khon Kaen province, Thailand, in June 2016. Authentication was identified by compar-
ison with the herbarium specimen at the Faculty of Science, Khon Kaen University. The
identified voucher specimen (KKU No. 21145) was deposited at Faculty of Pharmaceutical
Sciences, Khon Kaen Univerisity, Thailand. The root barks (2.29 kg) were air-dried, ground,
and sequentially extracted at room temperature for overnight with dichloromethane
(4 times). The extracts were evaporated in vacuo to obtain crude dichloromethane ex-
tract (140 g). The crude dichloromethane was isolated by open column chromatography on
silica gel 60 and subsequently eluted with a gradient of n-hexane and ethyl acetate (EtOAc)
to give 1 (310 mg; 1.4 × 10−2 of dry weight), 2 (340 mg; 1.5 × 10−2 of dry weight), and 3
(170 mg; 0.7 × 10−2 of dry weight). All isolated compounds were structurally elucidated
by comparison with the authentic samples, which were identical in all respects [34].
3.2. Purity Determination by HPLC-DAD
The HPLC system consisted of Shimadzu LC-20AD pump, equipped with a Shimadzu
DGV-20A5 degasser, a Rheodyne 7725i injector fitted with a 20 µL loop, and a SPD-M20A
DAD detector (Kyoto, Japan). Data acquisition was performed using Shimadzu LCMS
Lab Solutions software, version 3.50 SP2. The column used in this study was ACE-C18
(150 × 4.6 mm I.D., particle size 5 µm) manufactured by Advanced Chromatography
Technologies Ltd. (Aberdeen, Scotland, UK). The mobile phase composition was water and
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methanol (2:8 v/v; 0.1% triethylamine), all were HPLC grade solvents obtained from Merck
Life Science S.L.U. (Darmstadt, Germany). The flow rate was 1.0 mL/min and the UV
detection wavelength was 312 nm. Analyses were performed at 27 ◦C in an isocratic mode.
Peak purity index was determined by total peak UV-Vis spectra between 210–800 nm with
a step of 4 nm. The percentage is indicated at each compound and detailed data is given in
Supplementary Material.
3.3. General Semi-Synthesis of the Aminocarbazole Derivatives of Heptaphylline (1),
7-Methoxyheptaphylline (2), and 7-Methoxymukonal (3)
Naturally carbazole alkaloid heptaphylline (1, 40 mg, 0.132 mmol) or 7-methoxyhep-
taphylline (2, 41 mg, 0.132 mmol) or 7-methoxymukonal (3, 32 mg, 0.132 mmol) and
the amine precursors such as N,N,N-trimethyl-1,3-propanediamine (0.52 mL, 3.5 mmol,
27 equiv.) for compounds 1a, 2a, and 3a, or piperidine (0.1 mL, 3.5 mmol, 27 equiv.) for
compounds 1b and 2b, or 4-chlorobenzylamine (0.081 mL, 0.66 mmol, 5 equiv.) for com-
pounds 1c and 2c, or 4-fluorobenzylamine (0.075 mL, 0.66 mmol, 5 equiv.) for compounds
1d and 2d, or 4-bromobenzylamine (0.083 mL, 0.66 mmol, 5 equiv.) for compounds 1e
and 2e, or 1,2,3,4-tetrahydroisoquinoline (28 mg, 0.184 mmol, 1.4 equiv.) for compound
2f, were dissolved in dried THF or dried DCE, and added to the reaction mixture of the
STAB (84.8 mg, 0.36 mmol, 3 equiv.). After adding the acetic acid (8.2 µL, 0.132 mmol,
1equiv.), the mixture was stirred at r.t under N2 no longer than 14 days. For monitoring the
synthesis of aminocarbazole derivatives by TLC, two chromatographic systems were used:
n-hexane:EtOAc 7:3 and CHCl3:(CH3)2CO: TEA 100:0.1 for amine. The crude product
obtained from the reactions was subjected to different work-up strategies. After reaction of
compounds 1a, 1b, 2a, 2b, 2f, and 3a the crudes were extracted with CHCl3 (3 × 50 mL),
then solid phase extraction (SPE) through cation exchange cartridge Discovery® DSC-SCX
(Supelco, Bellefonte, Philadelphia, PA, USA) using 1% NH3 in CH3OH. The basic frac-
tions were purified on flash column using Hexane:EtOAc; 7:3. For compounds 1c, 1d,
1e and 2c, 2d, 2e, after reaction, the crudes extracts were treated with 5% of NaOH in
CHCl3 (3 × 50 mL) to remove excess STAB, the organic phases were treated with 5M HCl
in CHCl3 to remove excess amines. Then, the aqueous phases were treated with 20% of
NaOH in CHCl3. The combination of organic phases was subjected to SPE through cation
exchange cartridge Discovery® DSC-SCX using 1% NH3 in CH3OH. The basic fractions
were purified on flash column using n-hexane:EtOAc 7:3.
3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol
(1a). 25.2 mg; 49%; greenish yellow solid; purity HPLC-DAD 93.8%; mp: 160.3–161.2 ◦C;
IR (KBr) vmax cm−1: 3319, 2924, 1632, 1439, 1374, 1205, 740; 1H NMR (CDCl3, 300 MHz) δ:
7.92 (1H, br, NH), 7.89 (1H, d, J = 7.8 Hz, H-5), 7.53 (1H, s, H-4), 7.37 (1H, d, J = 7.9 Hz,
H-8), 7.28 (1H, ddd, J = 8.5, 7.0, 1.7 Hz, H-7), 7.15 (1H, dt, J = 7.5, 1.1 Hz, H-6), 5.36 (1H,
ddd, J = 6.8, 5.4 and 1.4 Hz, H-1”), 3.84 (2H, s, H-3′), 3.64 (2H, d, J = 6.7 Hz, H-1′), 2.56
(2H, t, J = 7.5 Hz, H-4′), 2.33 (3H, s, H-4”), 2.36 (2H, t, J = 7.5 Hz, H-6′), 2.23 (6H, s, H-6”),
1.90 (3H, s, H-2”), 1.76 (3H, d, J = 1.2 Hz, H-3”); 13C NMR (CDCl3, 75 MHz): 154.1 (C-2),
140.0 (C-8a), 139.4 (C-9a), 132.9 (C-2′), 124.0 (C-7), 123.8 (C-5a), 122.7 (C-1”), 119.3 (C-6),
119.1 (C-5), 117.6 (C-4), 115.4 (C-4a), 115.3 (C-3), 110.4 (C-8), 109.3 (C-1), 62.3 (C-3′), 57.4
(C-6′), 54.8 (C-4′), 45.3 (C-6”), 41.1 (C-4”), 25.8 (C-3”), 25.0 (C-5′), 18.1 (C-2”); HRMS-ESI
m/z 380.2697 (M + H)+ (calculate for C24H33N2O, 379.2624).
1-(3-Methylbut-2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-carbazol-2-ol (1b). 39.2 mg; 90%; green-
ish yellow oil; purity HPLC-DAD 95.8%; mp: 155.0–155.7 ◦C; IR (KBr) vmax cm−1: 3425,
2923, 1633, 1438, 1374, 1222, 741; 1H NMR (CDCl3, 300 MHz) δ: 7.90 (1H, br, NH), 7.89 (1H,
d, J = 7.7 Hz, H-5), 7.51 (1H, s, H-4), 7.36 (1H, d, J = 7.9 Hz, H-8), 7.29 (1H, ddd, J = 8.0, 6.8,
1.1 Hz, H-7), 7.15 (1H, dd, J = 7.1, 1.1 Hz, H-6), 5.37 (1H, ddd, J = 6.8, 5.1 and 1.3 Hz, H-1”),
3.81 (2H, s, H-3′), 3.65 (2H, d, J = 6.8 Hz, H-1′), 2.55 (4H, m, H-4′), 1.90 (3H, s, H-2”), 1.76
(3H, d, J = 1.2 Hz, H-3”), 1.65 (4H, m, H-5′), 1.51 (2H, m, H-6′); 13C NMR (CDCl3, 75 MHz):
154.3 (C-2), 140.0 (C-8a), 139.3 (C-9a), 132.9 (C-2′), 124.0 (C-7), 123.9 (C-5a), 122.7 (C-1”),
119.2 (C-6), 119.0 (C-5), 117.6 (C-4), 117.6 (C-3), 115.3 (C-4a), 115.0 (C-1), 110.3 (C-8), 62.8
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(C-3′), 53.7 (C-4′), 25.8 (C-5′), 25.7 (C-2”), 24.1 (C-6′), 23.8 (C-1′), 18.1 (C-3”); HRMS-ESI m/z
349.2270 (M + H)+ (calculated for C23H28N2O, 349.2280).
3-{[(4-Chlorobenzyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1c). 21.1 mg; 49%;
greenish yellow solid; purity HPLC-DAD 99.7%; mp: 98.3–99.6 ◦C; IR (KBr) vmax cm−1:
3420, 2917, 1635, 1463, 1378, 729, 668; 1H NMR (CDCl3, 300 MHz) δ: 7.93 (1H, br, NH), 7.89
(1H, d, J = 7.8 Hz, H-5), 7.55 (1H, s, H-4), 7.38 (1H, d, J = 7.8 Hz, H-8), 7.34–7.29 (2H, m,
H-6”), 7.28 (1H, ddd, J = 7.6, 5.1, and 3.4 Hz, H-7), 7.16 (1H, ddd, J = 9.1, 6.8 and 1.2 Hz,
H-6), 7.10–6.99 (2H, m, H-7”), 5.36 (1H, ddd, J = 6.8, 4.1 and 1.4 Hz, H-1”), 4.14 (2H, s, H-3′),
3.84 (2H, s, H-5′), 3.66 (2H, d, J = 6.7 Hz, H-1′), 1.91 (3H, s H-2”), 1.76 (3H, d, J = 1.2 Hz,
H-3”); 13C NMR (CDCl3, 75 MHz): 154.1 (C-2), 140.1 (C-9a), 139.4 (C-8a), 134.1 (C-6′), 133.0
(C-2′), 130.1 (C-6”), 130.0 (C-8′), 124.1 (C-7), 124.0 (C-5a), 123.9 (C-2”), 122.5 (C-1”), 119.3
(C-6), 119.1 (C-5), 117.7 (C-4), 115.6 (C-4a), 115.4 (C-7”), 115.2 (C-3), 110.4 (C-8), 109.8 (C-1),
52.5 (C-3′), 51.8 (C-5′), 23.9 (C-1′), 25.8 (C-2”), 18.1 (C-3”); HRMS-ESI m/z 405.1782 (M + H)+
(calculated for C25H25N2ClO, 405.1733).
3-{[(4-Fluorobenzyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1d). 38.5 mg; 42%;
greenish yellow solid; purity HPLC-DAD 98.8%; mp: 96.1–96.5 ◦C; IR (KBr) vmax cm−1:
3421, 2923, 1633, 1438, 1375, 1222, 741; 1H NMR (CDCl3, 300 MHz) δ: 7.92 (1H, br, NH), 7.89
(1H, d, J = 7.5 Hz, H-5), 7.55 (1H, s, H-4), 7.36 (1H, d, J = 7.5 Hz, H-8), 7.31 (2H, m, H-6”),
7.30 (1H, ddd, J = 8.5, 7.0, 1.7 Hz, H-7), 7.18 (2H, dt, J = 8.5 2.5 Hz, H-7”), 7.14 (1H, ddd,
J = 8.5, 7.0, 1.1 Hz, H-6), 5.36 (1H, ddd, J = 6.9, 4.6, and 1.5 H-1”), 4.14 (2H, s, H-3′), 3.84 (2H,
s, H-5′), 3.66 (2H, d, J = 6.7 Hz, H-1′), 1.91 (3H, d, J = 0.6 Hz, H-2”), 1.77 (3H, d, J = 1.2 Hz,
H-3”); 13C NMR (CDCl3, 75 MHz) 160.5 (C-7′), 154.3 (C-2), 140.2 (C-9a), 139.4 (C-8a), 136.9
(C-6′), 133.1 (C-2′), 130.1 (C-6”), 124.1 (C-7), 122.6 (C-1”), 119.7 (C-6), 119.6 (C-5), 117.8 (C-4),
115.9 (C-3), 115.8 (C-4a), 115.7 (C-5a), 115.5 (C-7”), 109.6 (C-1), 110.3 (C-8), 52.4 (C-3′), 51.8
(C-5′), 23.7 (C-1′), 25.8 (C-2”), 18.1 (C-3”); HRMS-ESI m/z 389.2023 (M + H)+ (calculated for
C25H25N2FO, 389.2062).
3-{[(4-Bromobenzyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1e). 40.66 mg;
64%; greenish yellow solid; purity HPLC-DAD 98.0%; mp: 145.6–146.4 ◦C; IR (KBr)
vmax cm−1: 3319, 2924, 1632, 1439, 1374, 1205, 740; 1H NMR (CDCl3, 300 MHz) δ: 7.92
(1H, br, NH), 7.90 (1H, d, J = 7.9 Hz, H-5), 7.55 (1H, s, H-4), 7.49 (2H, m, H-7”), 7.38 (1H,
d, J = 8.0 Hz, H-8), 7.31 (1H, ddd, J = 8.3, 7.5, 1.2, H-7), 7.21 (2H, dt, J = 8.5 2.5 Hz, H-6”),
7.16 (1H, ddd, J = 8.5, 7.0, 1.1 Hz, H-6), 5.36 (1H, m, H-1”), 4.14 (2H, s, H-3′), 3.83 (2H, s,
H-5′), 3.66 (2H, d, J = 6.8 Hz, H-1′), 1.91 (3H, s, H-2”), 1.77 (3H, d, J = 1.1 Hz, H-3”); 13C
NMR (CDCl3, 75 MHz) 153.7 (C-2), 140.2 (C-9a), 139.4 (C-8a), 138.9 (C-6′), 133.1 (C-2′), 131.8
(C-7”), 130.4 (C-6”), 124.5 (C-7), 123.6 (C-5a), 122.5 (C-1”), 121.5 (C-7′), 119.5 (C-6), 119.3
(C-5), 117.9 (C-4), 115.7 (C-3), 115.3 (C-4a), 109.8 (C-1), 110.6 (C-8), 52.5 (C-3′), 51.7 (C-5′),
23.6 (C-1′), 25.8 (C-2”), 18.1 (C-3”); HRMS-ESI m/z 447.471051 (M + H)+ (calculated for
C25H25N2BrO, 446.0994).
3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-
carbazol-2-ol (2a). 27.8 mg; 51.2%; greenish yellow solid; purity HPLC-DAD 96.8%; mp:
162.7–163.8 ◦C; IR (KBr) vmax cm−1: 3319, 2924, 1632, 1439, 1374, 1205, 740; 1H NMR
(CDCl3, 300 MHz) δ: 7.84 (1H, br, NH), 7.74 (1H, d, J = 8.5 Hz, H-5), 7.42 (1H, s, H-4),
6.88 (1H, d, J = 2.1 Hz, H-8), 6.78 (1H, dd, J = 8.5, 2.3 Hz, H-6), 5.35 (1H, m, H-1”), 3.88
(3H, s, H-7′), 3.82 (2H, s, H-3′), 3.62 (2H, d, J = 6.7 Hz, H-1′), 2.56 (2H, t, J = 7.3 Hz, H-4′),
2.42 (2H, t, J = 7.5 Hz, H-6′), 2.32 (9H, s, H-4” and 6”), 1.89 (3H, s, H-2”), 1.82 (2H, t,
J = 7.5 Hz, H-5′), 1.76 (3H, d, J = 1.1 Hz, H-3”); 13C NMR (CDCl3, 75 MHz) 157.9 (C-7),
153.1 (C-2), 140.6 (C-8a), 139.9 (C-9a), 132.9 (C-2′), 122.7 (C-1”), 119.7 (C-5), 117.9 (C-5a),
116.9 (C-4), 115.6 (C-4a), 115.1 (C-3), 109.4 (C-1), 107.7 (C-6), 95.0 (C-8), 62.3 (C-3′), 57.1
(C-6′), 55.7 (C-4′), 44.8 (C-6”), 41.1 (C-4”), 25.9 (C-3”), 24.2 (C-5′), 18.1 (C-2”); HRMS-ESI
m/z (calculated for C25H35N2O2, 409.2729).
7-Methoxy-1-(3-methylbut-2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-carbazol-2-ol (2b). 19.56 mg;
39%; greenish yellow oil; purity HPLC-DAD 98.3%; mp: 157.8–159.4 ◦C; IR (KBr) vmax cm−1:
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3397, 2919, 1652, 1449, 1361, 1035, 817, 784; 1H NMR (CDCl3, 300 MHz) δ: 7.84 (1H, br, NH),
7.74 (1H, d, J = 8.5 Hz, H-5), 7.41 (1H, s, H-4), 7.88 (1H, d, J = 2.2 Hz, H-8), 6.77 (1H, dd,
J = 8.5, 2.2 Hz, H-6), 5.56 (1H, m, H-1”), 3.88 (3H, s, H-7′), 3.79 (2H, s, H-3′), 3.63 (2H, d,
J = 6.7 Hz, H-1′), 2.63 (4H, m, H-4′), 1.90 (3H, s, H-2”), 1.76 (3H, d, J = 1.2 Hz, H-3”), 1.65 (4H,
m, H-5′), 1.48 (2H, m, H-6′); 13C NMR (CDCl3, 75 MHz): 157.8 (C-7), 153.4 (C-2), 140.5 (C-8a),
139.9 (C-9a), 132.9 (C-2′), 122.8 (C-1”), 119.7 (C-5), 117.9 (C-5), 116.9 (C-4), 115.5 (C-4a), 114.8
(C-1), 107.6 (C-6), 94.9 (C-8), 62.8 (C-3′), 53.7 (C-4′), 25.8 (C-5′), 25.7 (C-2”), 24.1 (C-6′), 23.8
(C-1′), 18.1 (C-3”); HRMS-ESI m/z 379.2382 (M + H)+ (calculated for C24H30N2O2, 378.2307).
3-{[(4-Chlorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2c).
19.60 mg; 34%; greenish yellow oil; purity HPLC-DAD 97.9%; mp: 109.8–110.2 ◦C; IR (KBr)
vmax cm−1: 3318, 2917, 1617, 1492, 1361, 1016, 801, 669; 1H NMR (CDCl3, 300 MHz) δ: 7.78
(1H, br, NH), 7.75 (1H, d, J = 8.5 Hz, H-5), 7.44 (1H, s, H-4), 7.32 (dt, 2H, J = 9.4, 3.0 Hz,
H-6”), 7.26 (m, 2H, H-7”), 6.89 (1H, d, J = 2.1 Hz, H-8), 6.78 (1H, dd, J = 8.5, 2.2 Hz, H-6),
5.35 (1H, m, H-1”), 4.12 (2H, s, H-3′), 3.88 (3H, s, H-7′), 3.82 (2H, s, H-5′), 3.64 (2H, d,
J = 6.7 Hz, H-1′), 1.90 (3H, s, H-2”), 1.76 (3H, d, J = 1.1 Hz, H-3”); 13C NMR (CDCl3, 75
MHz): 157.9 (C-7), 153.2 (C-2), 140.5 (C-8a), 140.0 (C-9a), 137.1 (C-6′), 133.3 (C-8′), 133.0
(C-2′), 129.8 (C-6”), 128.8 (C-7”), 122.6 (C-1”), 119.8 (C-5), 117.9 (C-5a), 116.9 (C-4), 115.7
(C-3), 115.5 (C-4a), 109.8 (C-1), 107.6 (C-6), 95.0 (C-8), 52.7 (C-3′), 51.8 (C-5′), 23.9 (C-1′),
25.8 (C-2”), 18.1 (C-3”); HRMS-ESI m/z 535.1838 (M + H)+ (calculated for C26H27ClN2O2,
434.1764).
3-{[(4-Fluorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2d).
16.64 mg; 30%; greenish yellow oil; purity HPLC-DAD 98.7%; mp: 94.2–95.1 ◦C; IR (KBr)
vmax cm−1: 3418, 2923, 1620, 1456, 1377, 1077, 1225, 803; 1H NMR (CDCl3, 300 MHz) δ:
7.84 (1H, br, NH), 7.75 (1H, d, J = 8.5 Hz, H-5), 7.45 (1H, s, H-4), 7.30 (dt, 2H, J = 9.4,
3.0 Hz, H-6”), 7.03 (2H, m, H-7”), 6.89 (1H, d, J = 2.2 Hz, H-8), 6.78 (1H, dd, J = 8.5, 2.2 Hz,
H-6), 5.29 (1H, m, H-1”), 4.12 (2H, s, H-3′), 3.88 (3H, s, H-7′), 3.83 (2H, s, H-5′), 3.75 (s, 1H,
NH), 3.64 (2H, d, J = 6.7 Hz, H-1′), 1.90 (3H, s, H-2”), 1.76 (3H, d, J = 1.1 Hz, H-3”); 13C
NMR (CDCl3, 75 MHz): 160.7 (C-8′), 157.9 (C-7), 153.2 (C-2), 140.6 (C-8a), 140.0 (C-9a),
134.4 (C-6′), 132.9 (C-2′), 130.0 (C-6”), 122.5 (C-1”), 119.7 (C-5), 117.9 (C-5a), 116.9 (C-4),
115.7 (C-4a), 115.4 (C-7”), 115.1 (C-3), 109.8 (C-1), 107.7 (C-6), 95.0 (C-8), 55.7 (C-7′), 52.6
(C-3′), 51.8 (C-5′), 25.8 (C-2”), 23.8 (C-1′), 18.1 (C-3”); HRMS-ESI m/z 419.2127 (M + H)+
(calculated for C26H27FN2O2, 418.2050).
3-{[(4-Bromobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2e).
54.64 mg; 86%; greenish yellow oil; purity HPLC-DAD 98.1%; mp: 117.1–118.4 ◦C; IR (KBr)
vmax cm−1: 3445, 2919, 1652, 1449, 1361, 801, 669; 1H NMR (CDCl3, 300 MHz) δ: 7.85 (1H, br,
NH), 7.75 (1H, d, J = 8.5 Hz, H-5), 7.48 (2H, m C-6”), 7.44 (1H, s, H-4), 7.21 (dd, 2H, J = 8.5,
2.5 Hz, H-6”), 6.89 (1H, d, J = 2.2 Hz, H-8), 6.78 (1H, dd, J = 8.5, 2.3 Hz, H-6), 5.35 (1H, m,
H-1”), 4.11 (2H, s, H-3′), 3.88 (3H, s, H-7′), 3.81 (2H, s, H-5′), 3.65 (2H, d, J = 6.7 Hz, H-1′),
1.90 (3H, s, H-2”), 1.76 (3H, d, J = 1.1 Hz, H-3”); 13C NMR (CDCl3, 75 MHz): 157.9 (C-7),
153.2 (C-2), 140.6 (C-8a), 140.0 (C-9a), 137.5 (C-6′), 132.9 (C-2′), 131.8 (C-6”), 130.1 (C-7”),
122.6 (C-1”), 121.4 (C-8′), 119.7 (C-5), 117.8 (C-5a), 116.9 (C-4), 115.7 (C-4a), 115.3 (C-3),
109.8 (C-1), 107.8 (C-6), 95.0 (C-8), 55.7 (C-7′), 52.6 (C-3′), 51.8 (C-5′), 25.8 (C-2”), 23.8 (C-1′),
18.1 (C-3”); HRMS-ESI m/z 179.1329 (M + H)+ (calculated for C26H27BrN2O2, 478.1256).
3-[(5-Amino-3,4-dihydroisoquinolin-2(1H)-yl)methyl]-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-
carbazol-2-ol (2f). 18.8 mg; 25.22%; orange solid; purity HPLC-DAD 98.9%; mp: 168.7–170.1 ◦C;
IR (KBr) vmax cm−1: 3387, 2919, 1617, 1449, 1361, 1257; 1H NMR (CDCl3, 300 MHz) δ: 7.86
(1H, br, NH), 7.76 (1H, d, J = 8.5 Hz, H-5), 7.49 (1H, s, H-4), 7.69 (1H, dd, J = 8.9 and 6.6 Hz,
H-11′), 6.89 (1H, d, J = 2.2 Hz, H-8), 6.79 (1H, dd, J = 8.5 and 2.2 Hz, H-6), 6.57 (1H, d,
J = 7.5 Hz, H-12′), 6.47 (1H, d, J = 7.5 Hz, H-10′), 5.35 (1H, ddd, J = 6.8, 5.4 and 1.4 Hz, H-1”),
4.00 (2H, s, H-3′), 3.89 (3H, s, H-7′), 3.57 (2H, s, H-6′), 3.60 (2H, d, J = 6.8 Hz, H-1′), 2.89 (2H,
t, J = 6.0 Hz, H-5′), 2.61 (2H, t J = 7.7 Hz, H-4′), 1.88 (3H, s, H-2”), 1.75 (2H, d J = 1.1 Hz,
H-3”); 13C NMR (CDCl3, 75 MHz): 157.8 (C-7), 154.1 (C-2), 144.1 (C-9′), 140.7(C-8a), 139.8
(C-9a), 136.3 (C-7′), 133.0 (C-2′), 126.4 (C-11′), 122.5 (C-1′), 119.8 (C-5), 119.5 (C-8′), 117.8
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(C-5a), 117.5 (C-4), 117.1 (C-12′), 115.7 (C-4a), 115.4 (C-3), 112.7 (C-10′), 109.6 (C-1), 107.6
(C-6), 95.1 (C-8), 56.7 (C-6′), 55.4 (C-7”), 52.8 (C-3′), 51.0 (C-4′), 25.7 (C-2”), 24.9 (C-5′), 23.9
(C-1′), 18.1 (C-3”); HRMS-ESI m/z 440.2323 (M + H)+ (calculated for C28H31N3O2, 441.2416).
3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-9H-carbazol-2-ol (3a) 23.27 mg;
51.38%; greenish yellow solid; purity HPLC-DAD 95.8%; mp: 148.2–150.0 ◦C; IR (KBr)
vmax cm−1: 3319, 2924, 1632, 1439, 1374, 1205, 740; 1H NMR (CDCl3, 300 MHz) δ: 7.99 (1H, br,
H-9), 7.75 (1H, d, J = 8.5 Hz, H-5), 7.53 (1H, s, H-4), 6.99 (1H, s, H-2′), 6.87 (1H, d, J = 2.1 Hz,
H-8), 6.83 (1H, s, H-1), 6.79 (1H, dd, J = 8.5, 2.3 Hz, H-6), 3.88 (3H, s, H-7′), 3.83 (2H, s, H-3′),
2.58 (2H, dd, J = 14.7 and 7.4 Hz, H-4′), 2.32 (3H, s, H-4”), 2.22 (6H, s, H-6”), 2.02 (2H, dd,
J = 14.3 and 6.8 Hz, H-6′), 1.76 (2H, dt J 14.7 and 7.4, H-6′); 13C NMR (CDCl3, 75 MHz)
157.9 (C-7), 153.1 (C-2), 140.6 (C-8a), 139.9 (C-9a), 132.9 (C-2′), 122.7 (C-1”), 119.7 (C-5), 117.9
(C-5a), 116.9 (C-4), 115.6 (C-4a), 115.1 (C-3), 109.4 (C-1), 107.7 (C-6), 95.0 (C-8), 62.3 (C-3′),
57.1 (C-6′), 55.7 (C-4′), 44.8 (C-6”), 41.1 (C-4”), 25.9 (C-3”), 24.2 (C-5′), 18.1 (C-2”); HRMS-ESI
m/z 342.2164 (M + H)+ (calculated for C20H27N3O2, 341.2103).
3.4. Crystallography
A single crystal was mounted on a cryoloop using paratone. X-ray diffraction data
were collected at room temperature with a Gemini PX Ultra (Rigaku/Oxford, Neu-Isenburg,
Germany) equipped with CuKα radiation (λ = 1.54184 Å). The structure was solved by
direct methods using SHELXS-97 [35] and refined with SHELXL-97 [35]. Crystal was mono-
clinic, space group P21/c, cell volume 2047.89(15) Å3 and unit cell dimensions a = 18.0056(9)
Å, b = 9.3592(3) Å, and c = 12.7126(6) Å and β = 107.074(5)◦ (uncertainties in parentheses).
Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were either placed
at their idealized positions using appropriate HFIX instructions in SHELXL and included
in subsequent refinement cycles or were directly found from difference Fourier maps and
were refined freely with isotropic displacement parameters. The refinement converged to
R (all data) = 12.46% and wR2 (all data) = 29.12%.
3.5. Yeast Screening Assay
Saccharomyces cerevisiae cells expressing human mutp53 R280K, Y220C, G245S, G245D,
R273C, R273H, R175H, R248W, R248Q, and R282W (or empty vector as control) were
obtained in previous works [36]. Yeast cells expressing human wtp53 were also obtained in
previous work [37] and were used as positive controls. For expression of human wtp53 or
mutp53, cells (routinely grown in minimal selective medium) were incubated in galactose
selective medium with all the amino acids required for yeast growth (50 µg/mL) except
leucine as described [36], in the presence of 10 µM of aminocarbazole derivatives, com-
pounds 1 and 1b–1d, or 0.1% DMSO, for approximately 42 h (time required by control yeast
incubated with DMSO to achieve 0.4 OD600). Yeast growth was analyzed by colony-forming
unit counts as described. Percentage of growth inhibition was calculated considering the
wtp53-induced yeast growth inhibition as 100%.
3.6. Human Tumor Cell Lines and Growths Conditions
Human colon adenocarcinoma HCT116 cell lines expressing wt p53 were provided
by B. Vogelstein (The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA); hu-
man colon adenocarcinoma HT-29, breast adenocarcinoma MDA-MB-468, colon cancer
SW837 and LS-1034, melanoma A375, glioblastoma SF-268, and non-tumorigenic foreskin
fibroblasts HFF-1 cell lines were purchase from American Type Culture Collection (ATCC).
Human hepatocarcinoma HuH-7 cell lines were purchase from JCRB cell bank. Tumor
cells were routinely cultured in RPMI-1640 medium with UltraGlutamine (Lonza, VWR,
Carnaxide, Portugal) supplemented with 10% fetal bovine serum (FBS; Gibco, Alfagene,
Lisboa, Portugal). HFF-1 cells were cultured in DMEM/F-12 supplemented with 10%
FBS. All cells were maintained at 37 ◦C in a humidified atmosphere of 5% CO2. Cells
were routinely tested for mycoplasma infection using the MycoAlert™ PLUS mycoplasma
detection kit (Lonza, VWR, Carnaxide, Portugal).
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3.7. Sulforhodamine B (SRB) Assay
Human cell lines were seeded in 96-well plates at a density of 5.0 × 103 (HCT116,
HuH-7, A375, HT-29, SW837, MDA-MB-468, SF-268 and LS-1034), and 1.0 × 104 (HFF-1)
cells/well, and allowed to adhere for 24 h. Cells were treated with serial dilutions of
compounds for additional 48 h. The effect on cell proliferation was measured by sulforho-
damine B (SRB) assay, as described [37], and IC50 (concentration that causes 50% growth
inhibition) values were determined for each cell line using the GraphPad Prism software
(version 6.0, GraphPad, San Diego, CA, USA).
4. Conclusions
A series of new semi-synthetic aminocarbazoles derived from carbazoles natural
products was successfully obtained and evaluated regarding the in vitro tumor growth
inhibition activity and potential ability to activate p53 of the compounds. The results
revealed a modest tumor growth inhibitory activity and no selectivity to the p53 pathway, in
human tumor cells for the natural products heptaphylline (1), 7-methoxy-heptaphylline (2),
and 7-methoxy-mukonal (3). Despite this, the results obtained indicate that aminocarbazole
semi-synthetic derivatives, particularly 3-(p-fluoro)aminoheptaphylline (1d), may represent
a promising starting point to search for new mutant p53-reactivating agents with promising
application in cancer therapy.
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ylmethyl)-9H-carbazol-2-ol (1b) (CDCl3, 75, MHz). Figure S6. HMBC spectrum of 1-(3-Methylbut-2-en-
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carbazol-2-ol (2a) CDCl3, 300, MHz). Figure S15: 13C NMR spectrum of 3-{[(3-(Dimethylamino)propyl)
(methyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2a) (CDCl3, 75, MHz).
Figure S16: HRMS spectrum of 3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-1-(3-
methylbut-2-en-1-yl)-9H-carbazol-2-ol (2a) (CDCl3, 300, MHz). Figure S17: 1H NMR spectrum of
7-Methoxy-1-(3-methylbut-2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-carbazol-2-ol (2b). (CDCl3, 300, MHz).
Figure S18: 13C NMR spectrum of 7-Methoxy-1-(3-methylbut-2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-
carbazol-2-ol (2b). (CDCl3, 75, MHz). Figure S19: HMBC spectrum of 7-Methoxy-1-(3-methylbut-
2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-carbazol-2-ol (2b). (CDCl3, 300, MHz). Figure S20: 1H NMR
spectrum of 3-{[(4-Chlorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2c),
(CDCl3, 300, MHz). Figure S21: 13C NMR spectrum of 3-{[(4-Chlorobenzyl)amino]methyl}-7-methoxy-1-
(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2c) (CDCl3, 75, MHz). Figure S22: HMBC spectrum of 3-{[(4-
Chlorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2c) (CDCl3, 300, MHz).
Figure S23: 1H NMR spectrum of 3-{[(4-Fluorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-
9H-carbazol-2-ol (2d) (CDCl3, 300, MHz). Figure S24: 13C NMR spectrum of 3-{[(4-Fluorobenzyl)amino]
methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2d) (CDCl3, 75, MHz). Figure S25: HMBC
spectrum of 3-{[(4-Fluorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2d)
(CDCl3, 300, MHz). Figure S26: 1H NMR spectrum 3-{[(4-Bromobenzyl)amino]methyl}-7-methoxy-1-
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(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2e) (CDCl3, 300, MHz). Figure S27: 13C NMR spectrum of
3-{[(4-Bromobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2e) (CDCl3, 75,
MHz). Figure S28: 13C NMR spectrum of 3-{[(4-Bromobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-
en-1-yl)-9H-carbazol-2-ol (2e) (CDCl3, 300, MHz). Figure S29: 1H NMR spectrum of 3-[(5-Amino-3,4-
dihydroisoquinolin-2(1H)-yl)methyl]-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2f). (CDCl3,
300, MHz). Figure S30: 13C NMR spectrum of 3-[(5-Amino-3,4-dihydroisoquinolin-2(1H)-yl)methyl]-7-
methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2f). (CDCl3, 75, MHz). Figure S31: 1H NMR spec-
trum of 3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-9H-carbazol-2-ol (3a) (CDCl3, 300,
MHz). Figure S32: 13C NMR spectrum of 3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-
9H-carbazol-2-ol (3a) (CDCl3, 75, MHz). Figure S33: HRMS of compound 3-{[(3-(Dimethylamino)propyl)
(methyl)amino] methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1a), (20, 300 V). Figure S34: HRMS of
compound 1-(3-Methylbut-2-en-1-yl)-3-(piperidin-1-ylmethyl)-9H-carbazol-2-ol (1b), (20, 300 V). Figure S35:
HRMS of compound of compound 3-{[(4-Chlorobenzyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-
carbazol-2-ol (1c), (20, 300 V). Figure S36: HRMS of compound 3-{[(4-Fluorobenzyl)amino]methyl}-
1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1d) (20, 300 V). Figure S37: HRMS of compound 3-{[(4-
Bromobenzyl)amino]methyl}-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (1e). (20, 300V). Figure S38: HRMS
of compound 3-{[(3-(Dimethylamino) propyl)(methyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-
9H-carbazol-2-ol (2a), (20, 300 V). Figure S39: HRMS of compound 3-{[(4-Chlorobenzyl)amino]methyl}-7-
methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2c), (20, 300 V). Figure S40: HRMS of compound
3-{[(4-Fluorobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2d), (20, 300 V).
Figure S41: HRMS of compound 3-{[(4-Bromobenzyl)amino]methyl}-7-methoxy-1-(3-methylbut-2-en-1-yl)-
9H-carbazol-2-ol (2e), (20, 300 V). Figure S42: HRMS of compound 3-[(5-Amino-3,4-dihydroisoquinolin-
2(1H)-yl)methyl]-7-methoxy-1-(3-methylbut-2-en-1-yl)-9H-carbazol-2-ol (2f), (20, 300 V). Figure S43: HRMS
of compound 3-{[(3-(Dimethylamino)propyl)(methyl)amino]methyl}-7-methoxy-9H-carbazol-2-ol (3a),
(20, 300 V).
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